Raymond James Adjusts Price Target on Boston Scientific to $88 From $97, Maintains Outperform Rating

robot
Abstract generation in progress

Raymond James has adjusted its price target for Boston Scientific (BSX) to $88, down from the previous $97, while reiterating an Outperform rating on the stock. This revision comes as the firm maintains its positive outlook on the medical technology company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin